MMP‐2 regulates Src activation via repression of the CHK/MATK tumor suppressor in osteosarcoma
Open Access
- 8 December 2023
- journal article
- research article
- Published by Wiley in Cancer Reports
- Vol. 7 (2) , e1946
Abstract
Background: Doxorubicin, a first‐line anticancer drug for osteosarcoma treatment, has been the subject of recent research exploring the mechanisms behind its chemoresistance and its ability to enhance cell migration at sublethal concentrations. Matrix metalloproteinase‐2 (MMP‐2), a type IV collagenase and zinc‐dependent endopeptidase, is well‐known for degrading the extracellular matrix and promoting cancer metastasis. Our previous work demonstrated that nuclear MMP‐2 regulates ribosomal RNA transcription via histone clipping, thereby controlling gene expression. Additionally, MMP‐2 activity is regulated by the non‐receptor tyrosine kinase and oncogene, Src, which plays a crucial role in cell adhesion, invasion, and metastasis. Src kinase is primarily regulated by two endogenous inhibitors: C‐terminal Src kinase (Csk) and Csk homologous kinase (CHK/MATK).Aim: In this study, we reveal that the MMP‐2 gene acts as an upstream regulator of Src kinase activity by suppressing its endogenous inhibitor, CHK/MATK, in osteosarcoma cells.Methods and Results: We show that enhanced osteosarcoma cell migration which is induced by sublethal concentrations of doxorubicin can be overcome by inactivating the MMP‐2 gene or overexpressing CHK/MATK. Our findings highlight the MMP‐2 gene as a promising additional target for combating cancer cell migration and metastasis. This is due to its role in suppressing on the gene and protein expression of the tumor suppressor CHK/MATK in osteosarcoma.Conclusion: By targeting the MMP‐2 gene, we can potentially enhance the effectiveness of doxorubicin treatment and reduce chemoresistance in osteosarcoma.Keywords
All Related Versions
Funding Information
- Research Foundation for the State University of New York (910252‐50)
This publication has 34 references indexed in Scilit:
- Tyrosine 416 Is Phosphorylated in the Closed, Repressed Conformation of c-SrcPLOS ONE, 2013
- Regulation of the Src Family Kinases by CskInternational Journal of Biological Sciences, 2012
- Src signaling in cancer invasionJournal of Cellular Physiology, 2010
- Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cellsBritish Journal of Cancer, 2009
- Decreased CHK protein levels are associated with Src activation in colon cancer cellsOncogene, 2007
- Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidaseCardiovascular Research, 2006
- Src oncogene activates MMP‐2 expression via the ERK/Sp1 pathwayJournal of Cellular Physiology, 2006
- A Novel Non-catalytic Mechanism Employed by the C-terminal Src-homologous Kinase to Inhibit Src-family Kinase ActivityJournal of Biological Chemistry, 2004
- Matrix metalloproteinase‐2 (MMP‐2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP‐ribose) polymerase (PARP) in vitroThe FASEB Journal, 2004
- Involvement of c‐Src in Carcinoma Cell Motility and MetastasisJapanese Journal of Cancer Research, 2001